Hidden Reason Ozempic Fails for Some: GLP-1 Resistance Revealed

More than one in four people with Type 2 diabetes use GLP-1 receptor agonists like Ozempic, a class of widely prescribed medications for blood sugar control and weight management. However, new research from Stanford Medicine and international collaborators suggests these drugs may be less effective for some individuals due to genetic differences, specifically GLP-1 resistance tied to variants in the PAM gene.

About 10% of the population carries certain genetic variants linked to this newly identified phenomenon. In these individuals, levels of the hormone GLP-1 (glucagon-like peptide-1), which helps regulate blood sugar by stimulating insulin release, slowing gastric emptying, and reducing appetite, are actually higher than normal but less effective at performing their job.

What Are GLP-1 Receptor Agonists and How Do They Work?

GLP-1 receptor agonists, such as Ozempic (semaglutide) and Wegovy, mimic the natural GLP-1 hormone produced in the gut. These medications bind to GLP-1 receptors on pancreatic beta cells to boost insulin secretion in response to meals, suppress glucagon release, delay gastric emptying for better post-meal glucose control, and promote satiety for weight loss. They are typically prescribed at lower doses for Type 2 diabetes and higher doses for obesity.

This mechanism explains their dual benefits, but variability in response has puzzled clinicians. The Stanford-led study, published March 29 in Genome Medicine, provides a genetic explanation after a decade of human, mouse, and clinical trial research.

Discovery of GLP-1 Resistance: A Genetic Culprit

"In some of the trials, we saw that individuals who had those variants were unable to lower their blood glucose levels as effectively after six months of treatment," said Anna Gloyn, DPhil, professor of pediatrics and of genetics, and one of the study's senior authors. At that point, a doctor would likely change the patient's drug regimen. Knowing ahead of time who is likely to respond would help patients get on the right drugs faster—a step toward precision medicine, Gloyn said.

The other senior author is Markus Stoffel, MD, PhD, professor of metabolic diseases at the Institute of Molecular Health Sciences, ETH Zurich in Switzerland. The lead authors are Mahesh Umapathysivam, MBBS, DPhil, an endocrinologist and clinical researcher at Adelaide University in Australia and a former trainee with Gloyn, and Elisa Araldi, PhD, associate professor of medicine and surgery at the University of Parma in Italy and a former trainee with Stoffel.

"When I treat patients in the diabetes clinic, I see a huge variation in response to these GLP-1-based medications and it is difficult to predict this response clinically," Umapathysivam said. "This is the first step in being able to use someone's genetic make-up to help us improve that decision-making process."

Although this is the most detailed investigation into GLP-1 resistance so far, the underlying biological mechanism remains unknown. "That is the million-dollar question," Gloyn said. "We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about. No matter what we've done, we've not been able to nail precisely why they are resistant."

PAM Gene Variants and Their Role in GLP-1 Resistance

The research focused on two specific genetic variants that affect an enzyme called PAM (peptidyl-glycine alpha-amidating monooxygenase). This enzyme plays a unique role in activating many hormones in the body, including GLP-1, through a chemical process called amidation, which increases the half-life or potency of biologically active peptides.

"PAM is a truly fascinating enzyme because it's the only enzyme we have that's capable of a chemical process called amidation, which increases the half-life or the potency of biologically active peptides," Gloyn said. "We thought, if you have a problem with this enzyme, there's going to be multiple aspects of your biology that are not working properly."

Previous research showed PAM variants are more common in people with diabetes and impair insulin release from the pancreas. The team investigated whether these variants also disrupt GLP-1 activity. Researchers studied adults with and without a PAM variant known as p.S539W. Participants drank a sugary solution, and their blood was tested every five minutes over four hours (in non-diabetic participants to minimize variables).

Contrary to expectations of lower GLP-1 levels, individuals with the PAM variant had increased levels of GLP-1. "What we actually saw was they had increased levels of GLP-1," Gloyn said. "This was the opposite of what we imagined we would find."

Despite higher circulating GLP-1, there was no evidence of higher biological activity—no faster blood sugar reduction. More GLP-1 was needed for the same effect, confirming GLP-1 resistance.

Clinical Relevance for Patients

For patients on Ozempic or similar drugs, this means genetic testing for PAM variants like p.S539W or p.D563G could predict poor response. Discuss genetic screening with your endocrinologist if you've experienced suboptimal blood sugar control or weight loss plateau after six months. Tools like Shotlee can help track daily symptoms, blood glucose trends, and medication responses to share with your doctor.

Confirming GLP-1 Resistance in Mouse Models

The unexpected findings prompted rigorous verification. "We couldn't understand this, which is why we looked as many different ways as we could to see if this was a really robust observation," Gloyn said.

Partners in Zurich studied mice lacking the PAM gene, which showed elevated GLP-1 levels failing to improve blood sugar control. These mice had faster gastric emptying, unaffected by GLP-1 drugs—one of GLP-1's key roles in blood sugar regulation and weight loss.

Reduced responsiveness appeared in the pancreas and gut, despite unchanged GLP-1 receptor numbers. Collaborators in Copenhagen confirmed no issues with GLP-1 binding or signaling, pointing to downstream pathway disruptions.

Clinical Trial Data: Reduced Response to GLP-1 Drugs

Analyzing three trials with 1,119 participants, those with PAM variants responded less to GLP-1 drugs and were less likely to reach target HbA1c levels. After six months, 25% of non-carriers met HbA1c targets vs. 11.5% with p.S539W and 18.5% with p.D563G.

Crucially, variants did not affect responses to sulfonylureas, metformin, or DPP-4 inhibitors. "What was really striking was that we saw no effect from whether you have a variant on your response to other types of diabetes medications," Gloyn said. "We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology."

Two pharma-funded trials with longer-acting GLP-1 drugs showed no differences, suggesting these formulations may bypass resistance.

Safety and Side Effects Context

GLP-1 drugs like Ozempic are generally safe, with common side effects like nausea or gastrointestinal issues. GLP-1 resistance doesn't alter these but highlights why some experience persistent hyperglycemia. No increased risks were noted for PAM carriers on non-GLP-1 therapies.

Implications for Weight Loss and Obesity Treatment

It remains unclear if PAM variants influence weight loss from Ozempic or Wegovy, used at higher doses for obesity. Only two trials had weight data, showing no clear differences, but data is limited. Longer-acting formulations may help.

Future Directions in Precision Medicine

Researchers noted GLP-1 resistance signs a decade ago. Accessing pharma genetic data could clarify poor responders. Gloyn compared it to insulin resistance: mechanism unknown, yet treatments exist. "There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance," she said.

Contributors included teams from University of Oxford, University of Dundee, University of Copenhagen, University of British Columbia, Churchill Hospital, Newcastle University, University of Bath, and University of Exeter. Funding came from Wellcome, Medical Research Council, EU Horizon 2020, NIH, and others.

Key Takeaways: What This Means for Patients

• 10% carry PAM variants causing GLP-1 resistance, leading to higher GLP-1 levels but poor blood sugar response.
• GLP-1 drugs like Ozempic less effective in carriers after 6 months (11.5-18.5% HbA1c success vs. 25%).
• No impact on other diabetes meds; longer-acting GLP-1s may overcome resistance.
• Genetic testing could guide therapy; track responses with apps like Shotlee.
• Precision medicine advances: match genetics to drugs for better outcomes.

Conclusion

This Stanford study illuminates why Ozempic fails for some, paving the way for tailored treatments. Patients should consult providers about genetic risks and alternatives like metformin if GLP-1 response lags. Stay informed on emerging research for optimal metabolic health management.